A detailed history of E Fund Management Co., Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 13,116 shares of APLS stock, worth $343,376. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,116
Previous 14,696 10.75%
Holding current value
$343,376
Previous $563,000 32.86%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$28.84 - $41.15 $45,567 - $65,017
-1,580 Reduced 10.75%
13,116 $378,000
Q2 2024

Aug 12, 2024

BUY
$38.07 - $59.71 $291,768 - $457,617
7,664 Added 108.99%
14,696 $563,000
Q1 2024

May 13, 2024

SELL
$55.39 - $72.47 $34,618 - $45,293
-625 Reduced 8.16%
7,032 $413,000
Q4 2023

Feb 06, 2024

SELL
$37.14 - $64.82 $124,084 - $216,563
-3,341 Reduced 30.38%
7,657 $458,000
Q3 2023

Nov 13, 2023

BUY
$23.65 - $89.22 $142,727 - $538,442
6,035 Added 121.6%
10,998 $418,000
Q2 2023

Aug 11, 2023

SELL
$76.68 - $93.31 $95,389 - $116,077
-1,244 Reduced 20.04%
4,963 $452,000
Q1 2023

May 11, 2023

SELL
$46.59 - $66.96 $111,676 - $160,503
-2,397 Reduced 27.86%
6,207 $409,000
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $67,194 - $94,856
1,554 Added 22.04%
8,604 $445,000
Q3 2022

Nov 14, 2022

SELL
$44.76 - $69.66 $161,180 - $250,845
-3,601 Reduced 33.81%
7,050 $482,000
Q2 2022

Aug 15, 2022

BUY
$35.07 - $59.21 $156,236 - $263,780
4,455 Added 71.9%
10,651 $482,000
Q1 2022

May 12, 2022

BUY
$35.46 - $54.12 $114,358 - $174,537
3,225 Added 108.55%
6,196 $315,000
Q1 2021

May 12, 2021

BUY
$40.8 - $57.39 $121,216 - $170,505
2,971 New
2,971 $127,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.88B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.